Original Articles Research Group Personalized Medicine

Original Articles Research Group Personalized Medicine (only published papers in international peer reviewed journals during the last 5 years) 1. Binkhorst L., Bannink M., de Bruijn P., Ruit J., Droogendijk H.J., van Alphen R.J., den Boer T.D., Lam M.H., Jager A., van Gelder T, and Mathijssen R.H.J. Augmentation of endoxifen exposure in tamoxifen-treated women following SSRIswitch. Clin. Pharmacokinet. (Epub October 2015). 2. Van Soest R.J., Nieuweboer A.J., de Morrée E.S., Chitu D., Bergman A.M., Goey S.H., Bos M.M.E.M., van der Meer N., Hamberg P., de Wit R., and Mathijssen R.H.J. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur. J. Cancer (Epub August 2015). 3. Huisman S.A., de Bruijn P., Moghaddam-Helmantel I.M., IJzermans J.N.M., Wiemer E.A.C., Mathijssen R.H.J., and de Bruin R.W.F. Fasting protects against the side-effects of irinotecan treatment but does not abrogate anti-tumor activity in mice. Br. J. Pharmacol. (Epub August 2015). 4. Nieuweboer A.J.M., Smid M., de Graan A.J.M., Elbouazzaoui S., de Bruijn P., Eskens F.A.L.M., Hamberg P., Martens J.W., Sparreboom A., de Wit R., van Schaik R.H.N., and Mathijssen R.H.J. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. Pharmacogenomics J. (Epub September 2015). 5. Diekstra M.H.M., Liu X., Swen J.J., Boven E., Castellano D., Gelderblom H., Mathijssen R.H.J., Rodríguez-Antona C., García-Donas J., Rini B.I., and Guchelaar H.J. Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. Eur. J. Clin. Pharmacol. 71 (12): 1477-1484, 2015. 6. Onstenk W., Sieuwerts A.M., Kraan J., Van M., Nieuweboer A.J.M., Mathijssen R.H.J., Hamberg P., Meulenbeld H.J., de Laere B., Dirix L.Y., van Soest R.J., Lolkema M.P.J.K., Martens J.W.M., van Weerden W.M., Jenster G.W., Foekens J.A., de Wit R., and Sleijfer S. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur. Urol. 68 (6): 939-945, 2015. 7. Crona D.J., Ramirez J., Qiao W., de Graan A.-J.M., Ratain M.J., van Schaik R.H.N., Mathijssen R.H.J., Rosner G.L., and Innocenti F. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. (Epub April 2015). 8. Lankhorst S., Baelde H.J., Kappers M.H.W., Smedts F.M.M., Hansen A., Clahsen-van Groningen M.C., Sleijfer S., Mathijssen R.H.J., Danser A.H.J., and van den Meiracker A.H. Greater sensitivity of blood pressure than renal toxicity to tyrosine-kinase receptor inhibition with sunitinib.

Hypertension 66 (3): 543-549, 2015. 9. Oosten A.W., Oldenmenger W.H., Mathijssen R.H.J., and van der Rijt C.C.D. A systematic review of studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J. Pain 16 (10): 935-946, 2015. 10. De Graan A.J.M., Sparreboom A., de Bruijn P., de Jonge E., van der Holt B., Wiemer E.A.C., Verweij J., Mathijssen R.H.J., and van Schaik R.H.N. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. Br. J. Clin. Pharmacol. 80 (3): 560-568, 2015. 11. Diekstra M.H.M., Swen J.J., Boven E., Castellano D., Gelderblom H., Mathijssen R.H.J., Rodríguez-Antona C., García-Donas J., Rini B.I., and Guchelaar H.J. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur. Urol. 68 (4): 621-629, 2015. 12. Binkhorst L., Kloth J.S.L., de Wit A.S., de Bruijn P., Lam M.H., Chaves-Machado I., Burger H., van Alphen R.J., Hamberg P., van Schaik R.H.N., Jager A., Koch B.C.P., Wiemer E.A.C., van Gelder T., van der Horst G.T.J., and Mathijssen R.H.J. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Breast Cancer Res. Treat. 152 (1): 119-128, 2015. 13. Drooger J.C., Jager A., Lam M.H., den Boer M.D., Sleijfer S., Mathijssen R.H.J., and de Bruijn P. Development and validation of an UPLC-MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair. J. Pharm. Biomed. Anal. 114: 416-425, 2015. 14. Burger H., den Dekker A.T., Segeletz S., Boersma A.W.M., de Bruijn P., Debiec- Rychter M., Taguchi T., Sleijfer S., Sparreboom A., Mathijssen R.H.J., and Wiemer E.A.C. Lysosomal sequestration determines intracellular imatinib levels. Mol. Pharm. 88 (3): 477-487, 2015. 15. Nieuweboer A.J.M., de Morree E.S., de Graan A.J.M., Sparreboom A., de Wit R., and Mathijssen R.H.J. Inter-patient variability in docetaxel pharmacokinetics: a review. Cancer Treat. Rev. 41 (7): 605-613, 2015. 16. Kloth J.S.L., Binkhorst L., de Wit A.S., de Bruijn P., Hamberg P., Lam M.H., Burger H., Chaves-Machado I., Wiemer E.A.C., van der Horst B.T.J., and Mathijssen R.H.J. Relationship between sunitinib pharmacokinetics and administration time: preclinical and clinical evidence. Clin. Pharmacokinet. 54 (8): 851-858, 2015. 17. Van Soest R.J., de Morrée E.S., Kweldam C.F., de Ridder C.M.A., Wiemer E.A.C., Mathijssen R.H.J., de Wit R., and van Weerden W.M. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur. Urol. 67 (6): 981-985, 2015.

18. Kraff S., Nieuweboer A.J.M., Mathijssen R.H.J., Baty F., de Graan A.J.M., van Schaik R.H.N., Jaehde U., and Joerger M. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Cancer Chemother. Pharmacol. 75 (5): 975-983, 2015. 19. Kloth J.S.L., Pagani A., Verboom M.C., Malovini A., Napolitano C., Kruit W.H.J., Sleijfer S., Steeghs N., Zambelli A., and Mathijssen R.H.J. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br. J. Cancer 112 (6): 1011-1016, 2015. 20. Van Leeuwen R.W.F., Jansman F.G.A., van den Bemt P.M.L., de Man F., Piran F., Vincenten I., Jager A., Rijneveld A.W., Brugma J.-D., Mathijssen R.H.J., and van Gelder T. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann. Oncol. 26 (5): 992-997, 2015. 21. Binkhorst L., Mathijssen R.H.J., Jager A., and van Gelder T. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping. Cancer Treat. Rev. 41 (3): 289-299, 2015. 22. Oza A., Cibula D., Oaknin Benzaquen A., Poole C., Mathijssen R.H.J., Sonke G.S., Colombo N., Špaček J., Vuylsteke P., Hirte H., Mahner S., Plante M., Schmalfeldt B., Mackay H., Rowbottom J., Lowe E.S., Dougherty B., Barrett J.C., and Friedlander M. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 16 (1): 87-97, 2015. 23. Lanvers-Kaminsky C., Sprowl J.A., Malath I., Deuster D., Eveslage M., Schlatter E., Mathijssen R.H.J., Boos J., Jürgens H.-J., am Zehnhoff-Dinnesen A.G., Sparreboom A., and Ciarimboli G. Human OCT2 variant c.808g>t confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 16 (4): 323-332, 2015. 24. Hamberg P., Mathijssen R.H.J., de Bruijn P., Leonowens C., van der Biessen D., Eskens F.A.L.M., Sleijfer S., Verweij J., and de Jonge M.J.A. Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. Cancer Chemother. Pharmacol. 75 (2): 365-371, 2015. 25. Toxopeus E.L.A., Talman S., van der Gaast A., Spaander V.M.C.W., van Rij C.M., Krak N.C., Biermann K., Tilanus H.W., Mathijssen R.H.J., van Lanschot J.J.B., and Wijnhoven B.P.L. Induction chemotherapy followed by surgery for advanced oesophageal cancer. Eur. J. Surg. Oncol. 41 (3): 323-332, 2015. 26. Van Pelt-Sprangers J.M., Geijteman E.C.T., Alsma J., Boere I.A., Mathijssen R.H.J., and Schuit S.C.E. Oromandibular dystonia: a serious side effect of capecitabine.

BMC Cancer 15 (1): 1132, 2015. 27. Yu H., Steeghs N., Kloth J.S.L., de Wit D., van Hasselt J.G.C., van Erp N.P., Beijnen J.H., Schellens J.H.M., Mathijssen R.H.J., and Huitema A.D.R. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br. J. Clin. Pharmacol. 79 (5): 809-819, 2015. 28. Lankhorst S., Kappers M.H.W., van Esch J.H.M., Smedts F.M.M., Sleijfer S., Mathijssen R.H.J., Baelde H.J., Danser A.H.J., and van den Meiracker A.H. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: Preclinical study. Hypertension 64 (6): 1282-1289, 2014. 29. Van der Biessen A.J., Burger H., de Bruijn P. Lamers C., Naus N., Loferer H., Wiemer E.A.C., Mathijssen R.H.J., and de Jonge M.J.A. Phase I study of RGB-286638, a novel, multi-targeted cyclin-dependent kinase inhibitor in patients with solid tumors. Clin. Cancer Res. 20 (18): 4776-4783, 2014. 30. Van Leeuwen R.W.F., van Gelder T., Mathijssen R.H.J., and Jansman F.G.A. Drug-drug interactions with tyrosine kinase inhibitors: a clinical perspective. Lancet Oncol. 15 (8): e315-e326, 2014. 31. Diekstra M.H.M., Klümpen H.J., Lolkema M.P.J.K., Yu H., Kloth J.S.L., Gelderblom A.J., van Schaik R.H.N., Gurney H., Swen J.J., Huitema A.D.R., Steeghs N., and Mathijssen R.H.J. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin. Pharmacol. Ther. 96 (1): 81-89, 2014. 32. Mathijssen R.H.J., Sparreboom A., and Verweij J. Determining the optimal dose in the development of anti-cancer agents. Nat. Rev. Clin. Oncol. 11 (5): 272-281, 2014. 33. Hu S., Mathijssen R.H.J., de Bruijn P., Baker S.D., and Sparreboom A. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br. J. Cancer 110 (4): 894-898, 2014. 34. Nieuweboer A.J.M., Hu S., Gui C., Hagenbuch B., Ghobadi Moghaddam-Helmantel I.M., Gibson A.A., de Bruijn P., Mathijssen R.H.J., and Sparreboom A. Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res. 74 (11): 3137-3145, 2014. 35. Ter Heine R., Binkhorst L., de Graan A.J.M., de Bruijn P., Beijnen J.H., Mathijssen R.H.J., and Huitema A.D.R. Population pharmacokinetic modeling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. Br. J. Clin. Pharmacol. 79 (3): 572-586, 2014. 36. Kloth J.S.L., Klümpen H.J., Yu H., Eechoute K., Samer C.F., Kam B.L.R., Huitema A.D.R., Daali Y., Zwinderman A.H., Balakrishnar B., Bennink R.J., Wong M., Schellens J.H.M., Mathijssen R.H.J., and Gurney H.

Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Clin. Pharmacokin. 53 (3): 261-269, 2014. 37. Schiavon G., Ruggiero A., Bekers D.J., Barry P.A., Sleijfer S., Kloth J., Krestin G.P., Schöffski P., Verweij J., and Mathijssen R.H.J. The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. Eur. J. Cancer 50 (5): 972-980, 2014. 38. Bins S., Ratain M.J., and Mathijssen R.H.J. Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin. Pharmacol. Ther. 95 (4): 361-364, 2014. 39. Hollestein L.M., van Herk-Sukel M.P.P., Ruiter R.T., de Vries E., Mathijssen R.H.J., Wiemer E.A.C., Stijnen T., Coebergh J.-W.W., Lemmens V.E.P.P., Herings R.M.C., Stricker B.H.Ch., and Nijsten T. Incident cancer risk after the start of aspirin use: Results from a Dutch populationbased cohort study of low dose aspirin users. Int. J. Cancer 135 (1): 157-165, 2014. 40. Van Jaarsveld M.T.M., Wouters M.D., Boersma A.W.M., Smid M., van IJcken W.F., Mathijssen R.H.J., Hoeijmakers J.H., Martens J.W.M., van Laere S., Wiemer E.A.C., and Pothof J. DNA damage responsive micrornas misexpressed in human cancer modulate therapy sensitivity. Mol. Oncol. 8 (3): 458-468, 2014. 41. Gits C.M.M., van Kuijk P.F., Jonkers M.B.E., Smid M., van IJcken W.F., Coindre J.-M., Chibon F., Verhoef C., Mathijssen R.H.J., den Bakker M.A., Verweij J., Sleijfer S., and Wiemer E.A.C. MicroRNA expression profiles distinguish liposarcoma subtypes and implicate mir-145 and mir-451 as tumor suppressors. Int. J. Cancer 135 (2): 348-361, 2014. 42. Lankheet N.A.G., Kloth J.S.L., Gadellaa-van Hooijdonk C.G.M., Cirkel G.A., Mathijssen R.H.J., Lolkema M.P.J.K., Schellens J.H.M., Voest E.E., Sleijfer S., de Jonge M.J.A., Haanen J.B., Beijnen J.H., Huitema A.D.R., and Steeghs N. Pharmacokinetically-guided sunitinib dosing: A feasibility study in patients with advanced solid tumors. Br. J. Cancer 110 (10): 2441-2449, 2014. 43. Gits C.M.M., van Kuijk P.F., de Rijck J.C.W.M., Muskens N., Jonkers M.B.E., van IJcken W.F., Mathijssen R.H.J., Verweij J., Sleijfer S., and Wiemer E.A.C. MicroRNA response to hypoxic stress in soft tissue sarcoma cells: microrna mediated regulation of HIF3. BMC Cancer 14 (1): 429, 2014. 44. Hamberg P., Boers-Sonderen M.J., van der Graaf W.T., de Bruijn P., Suttle A.B., Eskens F.A., Verweij J., van Herpen C.M., and Sleijfer S. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. Br. J. Cancer 110 (4): 888-893, 2014.

45. Van Soest R.J., van Royen M.E., de Morrée E.S., Moll J.M., Teubel W., Wiemer E.A.C., Mathijssen R.H.J., de Wit R., and van Weerden W.M. Preclinical evidence for cross-resistance between taxanes and abiraterone in castrationresistant prostate cancer. Eur. J. Cancer 49 (18): 3821-3830, 2013. 46. Van Jaarsveld M.T.M., Blijdorp I.C.J., Boersma A.W.M., Pothof J., Mathijssen R.H.J., Verweij J., and Wiemer E.A.C. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin. Eur J. Cancer 49 (2): 345-351, 2013. 47. Elens L., Nieuweboer A.J.M., Clarke S.J., Charles K.A., de Graan A.-J.M., Haufroid V., Mathijssen R.H.J., and van Schaik R.H.N. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics 14 (2): 137-149, 2013. 48. Elens L., Nieuweboer A.J.M., Clarke S.J., Charles K.A., de Graan A.J.M., Haufroid V., van Gelder T., Mathijssen R.H.J., and van Schaik R.H.N. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenet. Genomics 23 (3): 148-155, 2013. 49. Oudijk L., Gaal J., Korpershoek E., van Nederveen F.H., Kelly L., Schiavon G., Verweij J., Mathijssen R.H.J., den Bakker M.A., Oldenburg R.A., van Loon R.L.E., O Sullivan M.J., de Krijger R.R., and Dinjens W.N.M. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod. Pathol. 26 (3): 456-463, 2013. 50. Van Leeuwen R.W.F., Brundel D.H., Neef C., van Gelder T., Mathijssen R.H.J., Burger D.M., and Jansman F.G.A. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br. J. Cancer 108 (5): 1071-1078, 2013. 51. Van der Biessen A.J., Cranendonk M.A., Schiavon G., van der Holt B., Wiemer E.A.C., Eskens F.A.L.M., Verweij J., de Jonge M.J.A., and Mathijssen R.H.J. Evaluation of patient enrollment in oncology phase I clinical trials. Oncologist 18 (3): 323-329, 2013. 52. De Graan A.J.M., Elens L., Sprowl J., Sparreboom A., Friberg L.E., van der Holt B., de Raaf P.J., de Bruijn P., Engels F.K., Eskens F.A.L.M., Wiemer E.A.C., Verweij J., Mathijssen R.H.J., and van Schaik R.H.N. CYP3A4*22 and systemic exposure affect paclitaxel-induced dose-limiting neurotoxicity. Clin. Cancer Res. 19 (12): 3316-3324, 2013. 53. Binkhorst L., Mathijssen R.H.J., van Herk-Sukel M.P.P., Bannink M., Jager A., Wiemer E.A.C., and van Gelder T. Unjustified prescribing of CYP2D6 inhibiting SSRI s in women treated with tamoxifen. Breast Cancer Res. Treat. 139 (3): 923-929, 2013.

54. Van der Veldt A.A.M., Lubberink M., Mathijssen R.H.J., Loos W.J., Herder G.J.M., Greuter H.N., Comans E.F., Rutten H.B., Eriksson J., Windhorst A.D., Hendrikse N.H., Postmus P.E., Smit E.F., and Lammertsma A.A. Toward prediction of efficacy of chemotherapy: A proof of concept study in lung cancer patients using [ 11 C]docetaxel and positron emission tomography. Clin. Cancer Res. 19 (15): 4163-4173, 2013. 55. Van Jaarsveld M.T.M., Helleman J., Boersma A.W.M., van Kuijk P.F., van IJcken W.F., Despierre E., Vergote I., Mathijssen R.H.J., Berns E.M.J.J., Verweij J., Pothof J., and Wiemer E.A.C. mir-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 32 (36): 4284-4293, 2013. 56. De Graan A.J.M., Elens L., Smid M., Martens J.M.W., Sparreboom A., Elbouazzaoui S., Nieuweboer A., Wiemer E.A.C., van der Holt B., Verweij J., van Schaik R.H.N., and Mathijssen R.H.J. A pharmacogenetic predictive model for paclitaxel pharmacokinetics based on a DMET platform. Clin. Cancer Res. 19 (18): 5210-5217, 2013. 57. Gits C.M.M., van Kuijk P.F., Jonkers M.B.E., Boersma A.W., van IJcken W.F., Wozniak A., Sciot R., Rutkowski P., Schöffski P., Taguchi T., Mathijssen R.H.J., Verweij J., Sleijfer S., Debiec-Rychter M., and Wiemer E.A.C. MiR-17-92 and mir-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumors. Br. J. Cancer 109 (6): 1625-1635, 2013. 58. Sprowl J.A., van Doorn L., Hu S., van Gerven L., de Bruijn P., Li L., Gibson A.A., Mathijssen R.H.J., and Sparreboom A. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin. Pharmacol. Ther. 94 (5): 585-592, 2013. 59. Kunert A., Straetemans T., Govers C., Lamers C., Mathijssen R.H.J., Sleijfer S., and Debets R. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu (review). Front. Immunol. 4: 363, 2013. 60. Schiavon G., Ruggiero A., Schöffski P., van der Holt B., Bekers D.J., Eechoute K., Vandecaveye V., Krestin G.P., Verweij J., Sleijfer S., and Mathijssen R.H.J. Tumor volume as an alternative response measurement for imatinib treated GIST patients. Plos One 7 (11): e48372, 2012. 61. De Bruijn P., de Graan A.J.M., Nieuweboer A., Mathijssen R.H.J., Lam M.-H., de Wit R., Wiemer E.A.C., and Loos W.J. Quantification of cabazitaxel in human plasma by liquid chromatography / triplequadrupole mass spectrometry: a practical solution for non-specific binding. J. Pharm. Biomed. Anal. 59 (2): 117-122, 2012. 62. Ciarimboli G., Lancaster C.S., Schlatter E., Franke R.M., Sprowl J.A., Pavenstädt H., Massmann V., Guckel D., Mathijssen R.H.J., Yang W., Pui C.H., Relling M.V.,

Herrmann E., and Sparreboom A. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin. Cancer Res. 18 (4): 1101-1108, 2012. 63. Meulenbeld H.J., Mathijssen R.H.J., Verweij J., de Wit R., and de Jonge M.J.A. Danusertib, an aurora kinase inhibitor. Expert Opin. Investig. Drugs 21 (3): 383-393, 2012. 64. Kuip E.J.M., Zandvliet M.L., Mathijssen R.H.J., and van der Rijt C.C.D. Pharmacological and clinical aspects of immediate release fentanyl preparations: criteria for selection. Eur. J. Hosp. Pharm. 19 (1): 38-40, 2012. 65. Sprowl J.A., Gregorc V., Lazzari C., Mathijssen R.H.J., Loos W.J., and Sparreboom A. Associations between ABCC2 polymorphisms with cisplatin disposition and efficacy. Clin. Pharmacol. Ther. 91 (6): 1022-1026, 2012. 66. Schiavon G., Eechoute K., Mathijssen R.H.J., de Bruijn P., van der Bol J.M., Verweij J., Sleijfer S., and Loos W.J. Biliary excretion of imatinib and its active metabolite CGP74588 during severe liver dysfunction. J. Clin. Pharmacol. 52 (7): 1115-1120, 2012. 67. Binkhorst L., van Gelder T., Loos W.J., de Jongh F.E., Hamberg P., Ghobadi Moghaddam-Helmantel I.M., de Jonge E., Jager A., Seynaeve C., Van Schaik R.H.N., Verweij J., and Mathijssen R.H.J. Effects of CYP induction by rifampicin on tamoxifen exposure. Clin. Pharmacol. Ther. 92 (1): 62-67, 2012. 68. De Graan A.J.M., Loos W.J., Friberg L.E., Baker S.D., van der Bol J.M., van Doorn L., Wiemer E.A.C., van der Holt B., Verweij J., and Mathijssen R.H.J. Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy. Clin. Cancer Res. 18 (16): 4425-4432, 2012. 69. De Graan A.J.M., Lancaster C.S., Obaidat A., Hagenbuch B., Elens L., Friberg L.E., de Bruijn P., Hu S., Gibson A.A., Bruun G.H., Corydon T.J., Mikkelsen T.S., Walker A.L., Du G., Loos W.J., van Schaik R.H.N., Baker S.D., Mathijssen R.H.J., and Sparreboom A. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin. Cancer Res. 18 (16): 4433-4440, 2012. 70. Binkhorst L., van Gelder T., and Mathijssen R.H.J. Individualization of tamoxifen treatment in breast carcinoma. Clin. Pharmacol Ther. 92 (4): 431-433, 2012. 71. Eechoute K., van der Veldt A.A.M., Oosting S.F., Kappers M.H.W., Wessels J.A.M., Gelderblom H., Guchelaar H.-J., Reyners A.K.L., van Herpen C.M.L., Haanen J.B., Mathijssen R.H.J., and Boven E. Polymorphisms in endothelial nitric oxide synthase (enos) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin. Pharmacol Ther. 92 (4): 503-510, 2012.

72. Chatelut E., White-Koning M.L., Mathijssen R.H.J., Puisset F., Baker S.D., and Sparreboom A. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br. J. Cancer 107 (7): 1100-1106, 2012. 73. Eechoute K., Fransson M.N., Reijners A.K.L., de Jong F.A., Sparreboom A., van der Graaf W.T.A., Friberg L., Schiavon G., Wiemer E.A.C., Verweij J., Loos W.J., Mathijssen R.H.J., and de Giorgi U. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin. Cancer Res. 18 (20): 5780-5787, 2012. 74. Lancaster C.S., Bruun G.H., Peer C.J., Mikkelsen T.S., Corydon T.J., Gibson A.A., Hu S., Orwick S.J., Mathijssen R.H.J., Figg W.D., Baker S.D., and Sparreboom A. OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin. Pharmacol Ther. 92 (5): 642-650, 2012. 75. Mathijssen R.H.J., Loos W.J., and Verweij J. Determining the best dose for the individual patient. J. Clin. Oncol. 29 (33): 4345-4346, 2011. 76. Loos W.J., de Graan A.-J., de Bruijn P., van Schaik R.H.N., van Fessem M.A.C., Lam M.-H., Mathijssen R.H.J., and Wiemer E.A. Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3- methoxymorphinan, and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/ tandem triple-quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 54 (2): 387-394, 2011. 77. Engels F.K., Loos W.J., van der Bol J.M., de Bruijn P., Mathijssen R.H.J., Verweij J., and Mathôt R.A.A. Therapeutic drug monitoring for the individualization of docetaxel dosing: A randomized pharmacokinetic study. Clin. Cancer Res. 17 (2): 353-362, 2011. 78. Van der Bol J.M., Visser T.J., Loos W.J., de Jong F.A., Wiemer E.A., van Aken M.O., Planting A.S.Th., Schellens J.H.M., Verweij J., and Mathijssen R.H.J. Effects of methimazole on the elimination of irinotecan. Cancer Chemother. Pharmacol. 67: 231-236, 2011. 79. Eechoute K., Sparreboom A., Burger H., Franke R.M., Schiavon G., Verweij J., Loos W.J., Wiemer E.A.C., and Mathijssen R.H.J. Drug transporters and imatinib treatment: Implications for clinical practice. Clin. Cancer Res. 17 (3): 406-415, 2011. 80. Van der Veldt A.A., Eechoute K., Gelderblom H., Gietema J., Guchelaar H.J., van Erp N.P., van den Eertwegh A.J.M., Haanen J.B., Mathijssen R.H.J., and Wessels J.A.M. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin. Cancer Res. 17 (3): 620-629, 2011. 81. Van Doorn L., Eskens F.A.L.M., Visser T.J., van der Lugt A., Mathijssen R.H.J., and Peeters R.P.

Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 21 (2): 197-202, 2011. 82. Burger H., Loos W.J., Eechoute K., Verweij J., Mathijssen R.H.J., and Wiemer E. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist. Updates 14: 22-34, 2011. 83. Van der Bol J.M., Loos W.J., de Jong F.A., van Meerten E., Konings I.R.H.M., Lam M.H., de Bruijn P., Wiemer E.A.C., Verweij J., and Mathijssen R.H.J. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective open-label cross-over drug-interaction study. Eur. J. Cancer 47 (6): 831-838, 2011. 84. Klümpen H.-J., Samer C.F., Mathijssen R.H.J., Schellens J.H.M., and Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 37: 251-260, 2011. 85. Franke R.M., Lancaster C.S., Peer C.J., Gibson A.A., Kosloske A.M., Orwick S.J., Mathijssen R.H.J., Figg W.D., Baker S.D., and Sparreboom A. Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin. Pharmacol. Ther. 89 (5): 693-701, 2011. 86. Konings I.R.H.M., Sleijfer S., Mathijssen R.H.J., de Bruijn P., Ghobadi Moghaddam- Helmantel I.M., van Dam L.M., Wiemer E.A.C., Verweij J., and Loos W.J. Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. Cancer Chemother. Pharmacol. 67 (5): 1055-1062, 2011. 87. Eechoute K., Franke R.M., Loos W.J., Scherkenbach L.A., Boere I., Verweij J., Gurney H., Kim R.B., Tirona R.G., Mathijssen R.H.J., Sparreboom A. Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin. Pharmacol. Ther. 89: 816-820, 2011. 88. De Graan A.J.M., Teunissen S.F., de Vos F.Y.F.L., Loos W.J., van Schaik R.H.N., de Jongh F.E., de Vos A.I., van Alphen R.J., van der Holt B., Verweij J., Seynaeve C., Beijnen J., and Mathijssen R.H.J. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J. Clin. Oncol. 29 (24): 3240-3246, 2011. 89. Steeghs N., Mathijssen R.H.J., Wessels J.A.M., de Graan A.-J., van der Straaten T., Mariani M., Laffranchi B., Comis S., de Jonge M.J.A., Gelderblom H., and Guchelaar H.J. Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib. Invest. New Drugs 29 (5): 953-962, 2011. 90. Binkhorst L., Mathijssen R.H.J., Ghobadi Moghaddam-Helmantel I.M., de Bruijn P., van Gelder T., Wiemer E.A.C., and Loos W.J. Quantification of tamoxifen and three of its phase-i metabolites in human plasma by liquid chromatography / triple-quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 56 (5): 1016-1023, 2011.

91. Kappers M.H.W., van Esch J.H.M., Smedts F.M.M., de Krijger R.R., Eechoute K., Mathijssen R.H.J., Sleijfer S., Leijten F., Danser A.H.J., van den Meiracker A.H., and Visser T.J. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J. Clin. Endocrinol. Metab. 96 (10): 3087-3096, 2011. 92. Eechoute K., van Zonneveld M., van Daele P.L.A., Gerth van Wijk R., and Mathijssen R.H.J. Suppressing effect of sunitinib on allergic rhinitis: Previously undefined side effects with therapeutic potential. J. Clin. Pharmacol. 51 (11): 1592-1595, 2011. 93. Van der Bol J.M., de Jong F.A., van Schaik R.H.N., Sparreboom A., van Fessem M.A.C., van de Geijn F.E., van Daele P.L.A., Verweij J., Sleijfer S., and Mathijssen R.H.J. Influence of mannose-binding lectin polymorphisms on irinotecan-related treatment. Oncologist 15 (10): 1063-1072, 2010. 94. De Bruijn P., Sleijfer S., Lam M.-H., Mathijssen R.H.J., Wiemer E.A.C., and Loos W.J. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography / tandem triplequadrupole mass spectrometry. J. Pharm. Biomed. Anal. 51: 934-941, 2010. 95. Van der Bol J.M., Mathijssen R.H.J., Creemers G.J.M., Planting A.S.Th., Loos W.J., Wiemer E.A.C., Friberg L.E., Verweij J., Sparreboom A., and de Jong F.A. A CYP3A4 phenotype based dosing algorithm for individualized treatment of irinotecan. Clin. Cancer Res. 16 (2): 736-742, 2010. 96. Burger H., Zoumaro-Djayoon A., Boersma A.W.M., Helleman J., Berns E.M.J.J., Mathijssen R.H.J., Loos W.J., and Wiemer E.A.C. Differential transport of platinum compounds by the human organic cation transporter hoct2 (hslc22a2). Br. J. Pharmacol. 159: 898-908, 2010. 97. Franke R.M., Kosloske A.M., Lancaster C.S., Filipski K.K., Hu C., Zolk O., Mathijssen R.H.J., and Sparreboom A. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl- -Dglucosaminidase. Clin. Cancer Res. 16 (16): 4198-4206, 2010. 98. Pander J., Wessels J.A.M., Mathijssen R.H.J., Gelderblom H., and Guchelaar H.J. Pharmacogenetics of tomorrow: the 1+1=3 principle. Pharmacogenomics 11 (7): 1011-1017, 2010. 99. Lammers L.A., Mathijssen R.H.J., van Gelder T., Bijl M.J., de Graan A.-J.M., Seynaeve C., van Fessem M.A.C., Berns E.M.J.J., Vulto A.G., and van Schaik R.H.N. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br. J. Cancer 103 (6): 765-771, 2010. 100. de Jonge M.J.A., Slingerland M., Loos W.J., Wiemer E.A.C., Burger H., Mathijssen

R.H.J., Kroep J.R., den Hollander M.A.G., van der Biessen D., Lam M.-H., Verweij J., and Gelderblom H. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur. J. Cancer 46 (16): 3016-3021, 2010. Letters --------------------------------------- 1. Soest R.J., de Morrée E.S., Kweldam C.F., de Ridder C.M.A., Wiemer E.A.C., Mathijssen R.H.J., de Wit R., and van Weerden W.M. Reply to Shiota M., and Yokomizo A.: Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur. Urol. (Epub July 2015). 2. Lankhorst S., Mathijssen R.H.J., Danser A.H.J., and van den Meiracker A.H. Reply to Dingemanse J., and Clozel M.: Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib. Hypertension (Epub May 2015). 3. Van Leeuwen R.W.F., Mathijssen R.H.J., Jansman F.G.A., and van Gelder T. Reply to Conde-Estévez D. et al.; Potential clinical relevant drug-drug interactions: comparison between different compendia, do we have a validated method? Ann. Oncol. 26 (6): 1272-1273, 2015. 4. Van Leeuwen R.W.F., van Gelder T., Mathijssen R.H.J., and Jansman F.G.A. Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-author s reply. Lancet Oncol. 15 (11): e470-e471, 2014. 5. Sparreboom A., and Mathijssen R.H.J. Hepatic uptake transporters and docetaxel disposition in mice. Clin. Cancer Res. 20 (15): 4167, 2014. 6. Mathijssen R.H.J., de Bruijn P., Eechoute K., and Sparreboom A. Reply to Chatelut E., et al.; Long-term prospective population PK study in GIST patients -- response. Clin. Cancer Res. 19 (4): 950, 2013. 7. Koch B.C.P., van Schaik R.H.N., van Gelder T, and Mathijssen R.H.J. Doubt about the feasibility of preemptive genotyping. Clin. Pharmacol. Ther. 93 (3): 233, 2013. 8. Burger H., Mathijssen R.H.J., Sparreboom A., and Wiemer E.A.C. Can specific OCT1 inhibitors be used to determine OCT1 transporter activity towards imatinib? Blood 121 (24): 4965-4966, 2013. 9. De Bruijn P., Ghobadi Moghaddam-Helmantel I.M., Loos W.J., Mathijssen R.H.J., and Wiemer E.A.C. The issue of non-specific binding of cabazitaxel.

J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 932C: 74-75, 2013. 10. Sprowl J., Mathijssen R.H.J., and Sparreboom A. Can erlotinib ameliorate cisplatin-induced toxicities? J. Clin. Oncol. 31 (27): 3442-3443, 2013. 11. De Graan A.J.M., Binkhorst L., Loos W.J., van Schaik R.H.N., Verweij J., and Mathijssen R.H.J. Reply to Opdam F., et al.; Emphasizing the value of phenotyping in patients receiving tamoxifen. J Clin. Oncol. 30 (4): 465, 2012. 12. Van Erp N.P., Mathijssen R.H.J., van der Veldt A.A., Haanen J.B., Reyners A.K.L., Eechoute K., Boven E., Wessels J.A.M., Guchelaar H.J., and Gelderblom H. Myelosuppression by sunitinib is flt-3 genotype dependent. Br. J. Cancer 103 (5): 757-758, 2010. Book chapters --------------------------------------- 1. Schellens J.H.M., and Mathijssen R.H.J. Chapter 5: Clinical research-methodology in oncology (Dutch; 9 th edition). Oncologie (in press), 2015. 2. Schellens J.H.M., and Mathijssen R.H.J. Chapter 5: Clinical research-methodology in oncology (Dutch; 8 th edition). Oncologie 151-156, 2011. 3. De Jonge M.J.A., Mathijssen R.H.J., and Loos W.J. Chapter 13: Influence of polyfarmacy and age on the systemic exposure to chemotherapy. (Dutch; 1 st edition). Cancer in the Elderly 179-190, 2011. 4. Mathijssen R.H.J. Chapter 2: The treatment of cancer: what is the correct dose? (Dutch, 23 th edition). Anselmus Colloquium Cancer 26-39, 2011. 5. Mathijssen R.H.J., Beckeringh J.J., Durian M., and Schellens J.H.M. Chapter 17: Anti-cancer drugs (Dutch; 26 th edition). Farmacotherapeutisch Kompas 2010